Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v91,p1100)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, P.
Right arrow Articles by Bennett, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, P.
Right arrow Articles by Bennett, J.
Related Collections
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

International scoring system for evaluating prognosis in myelodysplastic syndromes

P Greenberg, C Cox, MM LeBeau, P Fenaux, P Morel, G Sanz, M Sanz, T Vallespi, T Hamblin, D Oscier, K Ohyashiki, K Toyama, C Aul, G Mufti and J Bennett

Hematology Division, Stanford University Medical Center, CA 94305, USA.

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: "good" outcomes were normal, -Y alone, del(5q) alone, del(20q) alone; "poor" outcomes were complex (ie, > or = 3 abnormalities) or chromosome 7 anomalies; and "intermediate" outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT- 1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.

Volume 89, Issue 6, pp. 2079-2088, 03/15/1997
Copyright © 1997 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JCOHome page
M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
J. Clin. Oncol., July 20, 2008; 26(21): 3607 - 3613.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. Mallo, L. Arenillas, B. Espinet, M. Salido, J. M{a} Hernandez, E. Lumbreras, M. del Rey, E. Arranz, S. Ramiro, P. Font, et al.
Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-
Haematologica, July 1, 2008; 93(7): 1001 - 1008.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, and J. Barrett
Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
J. Clin. Oncol., May 20, 2008; 26(15): 2505 - 2511.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. D. Nimer
Myelodysplastic syndromes
Blood, May 15, 2008; 111(10): 4841 - 4851.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
T. Hamada, H. Matsuura, T. Oono, S. Morizane, O. Yamasaki, K. Asagoe, T. Yamamoto, K. Tsuji, and K. Iwatsuki
Karyotypic Analysis of Bone Marrow Cells in Pyodermic Lesions Associated With Myelodysplastic Syndrome
Arch Dermatol, May 1, 2008; 144(5): 643 - 648.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Wimazal, W. R. Sperr, M. Kundi, A. Vales, C. Fonatsch, R. Thalhammer-Scherrer, I. Schwarzinger, and P. Valent
Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes
Ann. Onc., May 1, 2008; 19(5): 970 - 976.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Malcovati, M. Cazzola, and U. Germing
In Reply
J. Clin. Oncol., March 1, 2008; 26(7): 1181 - 1182.
[Full Text] [PDF]


Home page
haematolHome page
J.-J. Kiladjian, G. Visentin, E. Viey, S. Chevret, V. Eclache, J. Stirnemann, J. H. Bourhis, S. Chouaib, P. Fenaux, and A. Caignard
Activation of cytotoxic T-cell receptor {gamma}{delta} T lymphocytes in response to specific stimulation in myelodysplastic syndromes
Haematologica, March 1, 2008; 93(3): 381 - 389.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Valcarcel, R. Martino, D. Caballero, J. Martin, C. Ferra, J. B. Nieto, A. Sampol, M. T. Bernal, J. L. Pinana, L. Vazquez, et al.
Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival
J. Clin. Oncol., February 1, 2008; 26(4): 577 - 584.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. P. Gondek, R. Tiu, C. L. O'Keefe, M. A. Sekeres, K. S. Theil, and J. P. Maciejewski
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
Blood, February 1, 2008; 111(3): 1534 - 1542.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
Blood, February 1, 2008; 111(3): 1067 - 1077.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Kurzrock, H. M. Kantarjian, M. A. Blascovich, C. Bucher, S. Verstovsek, J. J. Wright, S. R. Pilat, J. E. Cortes, E. H. Estey, F. J. Giles, et al.
Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Clin. Cancer Res., January 15, 2008; 14(2): 509 - 514.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, V. Bardet, V. Coiteux, G. Leroux, P. Lepelley, M.-T. Daniel, et al.
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Blood, January 15, 2008; 111(2): 574 - 582.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood, January 1, 2008; 111(1): 86 - 93.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Haase, U. Germing, J. Schanz, M. Pfeilstocker, T. Nosslinger, B. Hildebrandt, A. Kundgen, M. Lubbert, R. Kunzmann, A. A. N. Giagounidis, et al.
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
Blood, December 15, 2007; 110(13): 4385 - 4395.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Grovdal, R. Khan, A. Aggerholm, P. Antunovic, J. Astermark, P. Bernell, L.-M. Engstrom, L. Kjeldsen, O. Linder, L. Nilsson, et al.
Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome
Clin. Cancer Res., December 1, 2007; 13(23): 7107 - 7112.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Mohamedali, J. Gaken, N. A. Twine, W. Ingram, N. Westwood, N. C. Lea, J. Hayden, N. Donaldson, C. Aul, N. Gattermann, et al.
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Blood, November 1, 2007; 110(9): 3365 - 3373.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan
Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
Oncologist, October 1, 2007; 12(10): 1264 - 1273.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb
Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation
J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al.
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
Blood, August 15, 2007; 110(4): 1379 - 1387.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Malcovati, U. Germing, A. Kuendgen, M. G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, et al.
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
J. Clin. Oncol., August 10, 2007; 25(23): 3503 - 3510.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
T. Siitonen, T. Timonen, E. Juvonen, V. Terava, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nylanden, et al.
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes
Haematologica, August 1, 2007; 92(8): 1119 - 1122.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
U. Germing, C. Strupp, S. Knipp, A. Kuendgen, A. Giagounidis, B. Hildebrandt, C. Aul, R. Haas, N. Gattermann, and J. M. Bennett
Chronic myelomonocytic leukemia in the light of the WHO proposals
Haematologica, July 1, 2007; 92(7): 974 - 977.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
D. P. Steensma
The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia
Haematologica, June 1, 2007; 92(6): 723 - 727.
[Full Text] [PDF]


Home page
haematolHome page
U. Bacher, T. Haferlach, W. Kern, C. Haferlach, and S. Schnittger
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
Haematologica, June 1, 2007; 92(6): 744 - 752.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Fenaux, A. Raza, G. J. Mufti, C. Aul, U. Germing, H. Kantarjian, L. Cripe, R. Kerstens, P. De Porre, and R. Kurzrock
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Blood, May 15, 2007; 109(10): 4158 - 4163.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Estey
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Y. Follo, S. Mongiorgi, C. Bosi, A. Cappellini, C. Finelli, F. Chiarini, V. Papa, M. Libra, G. Martinelli, L. Cocco, et al.
The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation
Cancer Res., May 1, 2007; 67(9): 4287 - 4294.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. A. Boumber, Y. Kondo, X. Chen, L. Shen, V. Gharibyan, K. Konishi, E. Estey, H. Kantarjian, G. Garcia-Manero, and J.-P. J. Issa
RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis
Cancer Res., March 1, 2007; 67(5): 1997 - 2005.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Aivado, D. Spentzos, U. Germing, G. Alterovitz, X.-Y. Meng, F. Grall, A. A. N. Giagounidis, G. Klement, U. Steidl, H. H. Otu, et al.
From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease
PNAS, January 23, 2007; 104(4): 1307 - 1312.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Ganser, M. A. Morgan, and E. M. Weissinger
Going from genes to proteins in myelodysplastic syndromes
PNAS, January 23, 2007; 104(4): 1109 - 1110.
[Full Text] [PDF]


Home page
haematolHome page
W. Barcellini, A. Zaninoni, F. G. Imperiali, C. Boschetti, M. Colombi, A. Iurlo, and A. Zanella
Anti-erythroblast autoimmunity in early myelodysplastic syndromes
Haematologica, January 1, 2007; 92(1): 19 - 26.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen
Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Hematology, January 1, 2007; 2007(1): 392 - 397.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. Melchert and A. F. List
Management of RBC-Transfusion Dependence
Hematology, January 1, 2007; 2007(1): 398 - 404.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. Garcia-Manero
Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia
Hematology, January 1, 2007; 2007(1): 405 - 411.
[Abstract] [Full Text] [PDF]


Home page
ASH-SAPHome page
K. Shannon and L. R. Silverman
Myelodysplastic syndrome and overlap syndromes
ASH Self-Assessment Program, January 1, 2007; 2007(1): 228 - 242.
[Full Text] [PDF]


Home page
BloodHome page
T. A. Navas, M. Mohindru, M. Estes, J. Y. Ma, L. Sokol, P. Pahanish, S. Parmar, E. Haghnazari, L. Zhou, R. Collins, et al.
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors
Blood, December 15, 2006; 108(13): 4170 - 4177.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Kuendgen, C. Strupp, M. Aivado, B. Hildebrandt, R. Haas, N. Gattermann, and U. Germing
Myelodysplastic Syndromes in Patients Younger Than Age 50
J. Clin. Oncol., December 1, 2006; 24(34): 5358 - 5365.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone, et al.
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
N. Engl. J. Med., October 5, 2006; 355(14): 1456 - 1465.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. Agool, B. W. Schot, P. L. Jager, and E. Vellenga
18F-FLT PET in Hematologic Disorders: A Novel Technique to Analyze the Bone Marrow Compartment
J. Nucl. Med., October 1, 2006; 47(10): 1592 - 1598.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Szpurka, R. Tiu, G. Murugesan, S. Aboudola, E. D. Hsi, K. S. Theil, M. A. Sekeres, and J. P. Maciejewski
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
Blood, October 1, 2006; 108(7): 2173 - 2181.
[Abstract] [Full Text] [PDF]